FTSE 100 Facebook Twitter Email Calculators

FTSE 100

  1. 84.31%
    10.78%
    4.9%
  2. Currency Converter

    Convert currencies using the lastest exchange rates

Calculators

  1. Mortgage Calculator

    See how much mortgage you can have
    Calculate Mortgage
  2. Debt Calculator

    Work out how we can help you manage your debt
    Calculate Debt
Contact us...

Moneyextra News
NULL

Last weeks top customer buys and sells from The Share Centre

Sheridan Admans, investment research manager at The Share Centre,...

Read More...
NULL

Aviva report a solid start to 2012 for investors

Aviva generated £0.5bn operating capital in the first quarter....

Read More...
NULL

Forced early Greek election could restore market confidence sooner

A concern over a lack of faith in any political leadership in Greece...

Read More...
NULL

Tullow Oil remains attractive for high risk investors

Excellent record of turning oil discoveries into productive assets...

Read More...

Falling profit margins wound Smith & Nephew

Smith & Nephew makes amends to cut costs

Poor orthopaedic trading margin impacts performance
The Share Centre puts ‘hold’ recommendation under review

As Smith & Nephew reports disappointing Q3 figures, Nick Raynor, investment research analyst at The Share Centre, explains what they mean for investors.
 
Smith & Nephew reported sales figures that were largely in line with expectations, with revenue increasing by 10%, and underlying growth rising by 5%. However, poor margins in its orthopaedics side of the business put pressure on the company’s performance. The 15.6% margin, which was short of analyst expectations, was caused by high periodic costs, adverse sales mix and the need to reduce costs to reflect market conditions.   
 
“The company has been attempting to improve margins by cost cutting for some time. However, these figures have shown the cost base is still too high. Although Smith & Nephew have restructuring plans in place, we doubt these will be implemented by the end of the year, which could see crippling margins impede final year results.   
 
“Concerns remain over the US health system and with no signs of the credit crunch easing, we could see Smith & Nephew’s profitability fall further. The company generates a large proportion of its business from elective procedures, however, as worry over employment remains, people are opting to wait for the national healthcare system.
 
“The market reacted to these disappointing figures with the share price falling by as much as 6% in early morning trading. Following these results our current ‘hold’ recommendation looks weak and Smith & Nephew is now under review.”
 
 
 
THIS DATA IS PROVIDED BY THE SHARE CENTRE. THIS IS NOT INTENDED TO CONSTITUTE AN OFFER OR AGREEMENT TO BUY OR SELL INVESTMENTS.

Risk Warnings:

Investing in general, and the products and services mentioned above may not be suitable for all: if in doubt, individuals should seek independent financial advice. The value of investments and the income from them can go down as well as up and investors may not get back their original investment. Past performance is not a reliable indicator of future performance.

The bases and levels of taxation relating to ISAs, CTFs and SIPPs are subject to change and the value of these tax allowances may depend upon the circumstances of the individual.

Moneyextra.com recommends you take independent financial advice before acting on any article

Back

2011-11-04 13:07:44 © Moneyextra.com